Gain-of-function mutations in PPM1D leading to expression of a stable PPM1D protein have been implicated in solid tumors (including breast [26, 63], colon cancer [27], and glioma [64, 65]) and in age-related or therapy-induced clonal hematopoiesis [28, 29]. Here, PPM1D is linked to central nervous system cancer.